News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE) Affirms Celebrex Safety


10/19/2005 5:12:05 PM

NEW YORK, Nov. 4 /PRNewswire-FirstCall/ -- Pfizer Inc today issued the following statement in response to a report in Canada's National Post newspaper concerning the cardiovascular safety of Celebrex:

The news report, based on voluntary spontaneous event reporting to Canadian Health authorities, is misleading. The story is not supported by any clinical or epidemiological studies and has the potential to cause undue confusion among patients and physicians.

The safety profile for Celebrex is well-established and is supported by extensive clinical studies in Canada and around the world.

Voluntary spontaneous event reporting to health authorities is not designed and cannot be used to determine cause and effect. It is essential to remember that the information provided is uncontrolled and may be second-hand or incomplete.

Health Canada has acknowledged these limitations, noting "there hasn't been a causal link established". The agency has also noted that these data contain no information about patients' underlying medical conditions.

Millions of patients have been prescribed Celebrex since its first approval in 1998 and large-scale clinical studies of up to four years showed no increased cardiovascular safety risk.

Photo: A free corporate logo to accompany this story is availableimmediately via Wieck Photo Database to any media with telephoto receiver orelectronic darkroom, PC or Macintosh, that can accept overhead transmissions.To retrieve a logo, please call 972-392-0888. Pfizer Inc

CONTACT: Paul Fitzhenry, +1-212-733-4637, or Susan Bro, +1-212-733-5554,both of Pfizer Inc

Company News On-Call: http://www.prnewswire.com/comp/688250.html

Company News On-Call: Pfizer's press releases are available through PRNewswire's Company News On-Call service on PRN's Web Site. Visithttp://www.prnewswire.com/comp/688250.html


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES